Skip to content

Clinical benefit of nocturnal infusion of dexmedetomidine on postoperative sleep disturbance in patients undergoing gastrointestinal tumor surgery

Clinical benefit of nocturnal infusion of dexmedetomidine on postoperative sleep disturbance in patients undergoing gastrointestinal tumor surgery

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069037
Enrollment
Unknown
Registered
2023-03-05
Start date
2023-03-01
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep disorder

Interventions

DEX:nocturnal infusion of dexmedetomidine
CON:nocturnal infusion of normal saline

Sponsors

The First Affiliated Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Scheduled gastrointestinal tumor resection 2. =18 years old 3. ASA Grade I-IV.

Exclusion criteria

Exclusion criteria: 1.Allergic to dexmetomidine. 2.Preoperative chemotherapy, radiotherapy or immunotherapy. 3.Severe cognitive impairment. 4.Neurological disease and neurological injury that may effect on sleep quality 5.Sick sinus syndrome, persistent bradycardia requiring intervention, severe abnormalities of cardiac conduction system (second or third-degree atrioventricular block) and severe ventricular dysfunction, severe hemodynamic instability 6.Patients with alcohol or drug dependence, long-term use of opioids, benzodiazepines, and other drugs known to affect sleep structure. 7.Chronic sleep disorder. 8.Significant kidney disease (stage 4 kidney disease or higher) and liver disease (Child-Pugh B or C class). 9.Pregnancy or breastfeeding. 10.Refuse to participate.

Design outcomes

Primary

MeasureTime frame
RCSQ total scores;

Secondary

MeasureTime frame
Objective sleep monitoring data;NRS;PSQI score;Surgical complications;

Countries

China

Contacts

Public ContactWenqi Huang

The First Affiliated Hospital, Sun Yat-sen University

huangwq@mail.sysu.edu.cn13802963182

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026